Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

FDA ADVISORY
No. 20232596

29 DEC 2023

TO : **ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

SUBJECT : **Public Health Warning Against the Purchase and Use of the following Verified Counterfeit Drug Products:**

1. **Ibuprofen + Paracetamol (Alaxan®FR) 200 mg/ 325 mg Capsule**
2. **Loperamide (Diatabs®) 2 mg Capsule**
3. **Ibuprofen (Medicol® Advance) 200 mg Softgel Capsule**

The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following products:

AUTHENTIC



COUNTERFEIT



Counterfeit – The lot number, capsule, knurling, and print appearance are not comparable with the standard features of the registered product.

Figure 1. Comparison between the Authentic and Verified Counterfeit Ibuprofen + Paracetamol (Alaxan®FR) 200 mg / 325 mg Capsule (Lot No. 66727082, Exp. Date MAY 2026)

AUTHENTIC



COUNTERFEIT



Counterfeit – The lot number, tablet, knurling, and print appearance are not comparable with the standard features of the registered product.

Figure 2. Comparison between the Authentic and Verified Counterfeit Loperamide (Diatabs®) 2 mg Capsule (Lot No. U062088, Exp. Date MAY 2028)

AUTHENTIC



COUNTERFEIT



Counterfeit – The lot number, capsule, knurling, and print appearance are not comparable with the standard features of the registered product.

Figure 3. Comparison between the Authentic and Verified Counterfeit Ibuprofen (Medicol® Advance) 200 mg Softgel Capsule (Lot No. E002939, Exp. Date APR 2026)

All healthcare professionals and the general public are hereby warned as to the availability of these counterfeit drug products in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug products only from FDA-licensed establishments.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit products with the abovementioned features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug products will be penalized.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction

For more information and inquiries, please e-mail us at **info@fda.gov.ph**. To report continuous sale or distribution of unregistered health products, kindly e-mail us via **ereport@fda.gov.ph**. You may also call the Center for Drug Regulation and Research at telephone number **(02) 8809-5596**. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: **https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH** and fill out all the required fields.

Dissemination of the information to all concerned is requested.

DR. SAMUEL A. ZACATE
Director General

DTN: 20231128141528

Center for Drug Regulation and Research	
Lanette Lee A. Querubin, RPh, MSc Chief, PRSDD	**JESUSA JOYCE N. CIRUNAY, RPh** Director IV

Keywords	Ibuprofen + Paracetamol (Alaxan®FR) 200 mg / 325 mg Capsule (Lot No. 66727082, Exp. Date MAY 2026), Phenylephrine Hydrochloride + Chlorphenamine Maleate + Paracetamol (Bioflu®) 10 mg/ 2mg/ 500 mg Film-Coated Tablet (Lot No. U298349, Exp. Date 04/2025), Ibuprofen (Medicol® Advance) 200 mg Softgel Capsule (Lot No. E002939, Exp. Date APR 2026)
Related issuances, laws, directives	Republic Act No. 9711 and its Implementing Rules and Regulations